Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...

It marks the second such rejection in the UK for an Alzheimer’s treatment, after Eisai and Biogen’s drug met the same fate ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...